[Childhood Graves' disease].
Because of the low frequency of childhood Graves' disease, detailed evidence-based clinical studies have not been reported. Practical clinical work has been performed on the basis of adult clinical references. Therapeutic management includes antithyroid drugs, surgical thyroidectomy and radiologic therapy. Recently in the U.S.A. radiotherapy has become the recommended course of action, even for childhood Graves' disease, whereas in Japan, antithyroid drug therapy is the primary course of action for childhood Graves' disease. In some cases, thyroidectomy is performed following drug therapy. Methimazole (MMI) and propylthiouracil (PTU) have been used, however, MMI is the preferred drug treatment. Compared to PTU, MMI is administered once a day and the frequency of side effects is lower than that of PTU. Evaluation of the TSH receptor antibody value before administration of antithyroid drugs is very useful in estimating the duration of the treatment. No appropriate index has been established guiding when to quit antithyroid drug therapy.
Sasaki
Nozomu
N
Department of Pediatrics, Saitama Medical University.
Sato
Koichi
K
D013956:Antithyroid Agents / Q000008:administration & dosage / Q000009:adverse effects; D001323:Autoantibodies / Q000032:analysis; D015415:Biomarkers / Q000032:analysis; D002648:Child; D003131:Combined Modality Therapy; D006111:Graves Disease / Q000175:diagnosis / Q000628:therapy*; D006801:Humans; D018828:Immunoglobulins, Thyroid-Stimulating; D008713:Methimazole / Q000008:administration & dosage / Q000009:adverse effects; D011441:Propylthiouracil / Q000008:administration & dosage / Q000009:adverse effects; D011878:Radiotherapy; D013965:Thyroidectomy
D013956:Antithyroid Agents; D001323:Autoantibodies; D015415:Biomarkers; D018828:Immunoglobulins, Thyroid-Stimulating; C094372:thyrotropin-binding inhibitory immunoglobulin; D008713:Methimazole; D011441:Propylthiouracil